 Gossamer Bio Inc NASDAQ: GOSS shares are falling after announcing topline results from its Phase 2 SHIFT-UC Study trial of GB004 in patients with mild-to-moderate active ulcerative colitis UC. Neither GB004 treatment arm met the primary or secondary endpoints at week 12. 